Newswire (Published: Friday, November 24, 2017, Received: Thursday, November 16, 2017, 12:35:11 PM CST)
Word Count: 549
New Prostate-Specific Antigen Study Findings Have Been Reported by Researchers at Diagnostica Stago (US Preventive Services Task Force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses)
By a News Reporter-Staff News Editor at Health & Medicine Week -- New research on Enzymes and Coenzymes - Prostate-Specific Antigen is the subject of a report. According to news reporting originating in Hackensack, New Jersey, by NewsRx journalists, research stated, "To evaluate the impact that the 2012 US Preventive Services Task Force (USPSTF) prostate-specific antigen (PSA) screening guidelines have had on the diagnosis of prostate cancer, we compared the incidence and distribution of new cases diagnosed in 2011-before the USPSTF PSA screening recommendations versus 2014 at which time the guidelines were widely adopted. We identified all prostate biopsies performed by a large urology group practice utilizing a centralized pathology lab."
The news reporters obtained a quote from the research from Diagnostica Stago, "We examined total biopsies performed, percentage of positive biopsies, and for those with positive biopsies examined for differences in patient age, PSA, and Gleason score. A total of 4,178 biopsies were identified -2,513 in 2011 and 1,665 in 2014. The percentage of positive biopsies was 27% in 2011 versus 34% in 2014 (p <0.0001). Among patients with positive biopsies, we found statistically significant differences between the 2 cohorts in the median ages and Gleason scores. Patients were about 1 year younger in 2014 compared to 2011 (t-test; p=0.043). High Gleason scores (8-10) were diagnosed in 19% of the 2014 positive biopsies versus 9% in the 2011 positive biopsies (chi square; p<0.0001). After the widespread implementation of the 2011 USPTF PSA screening guidelines, 34% fewer biopsies were performed with a 29% increase in positive biopsy rates. We found a significantly higher incidence of high grade disease in 2014 compared with 2011. The percentage of patients with positive biopsies having Gleason scores 8-10 more than doubled in 2014."
According to the news reporters, the research concluded: "The higher incidence of these more aggressive cancers must be part of the discussion regarding PSA screening."
For more information on this research see: US Preventive Services Task Force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses. Investigative and Clinical Urology, 2017;58(6):423-428 (see also Enzymes and Coenzymes - Prostate-Specific Antigen).
Our news correspondents report that additional information may be obtained by contacting G. Gejerman, New Jersey Urology, Hackensack University Medical Center, Hackensack, NJ, United States. Additional authors for this research include P. Ciccone, M. Goldstein, V. Lanteri, B. Schlecker, J. Sanzone, M. Esposito, S. Rome, M. Ciccone, E. Margolis, R. Simon, Y. Guo, S.R. Pentakota and H. Sadhegi-Nejad.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.4111/icu.2017.58.6.423. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
Keywords for this news article include: Hackensack, New Jersey, Kallikreins, United States, Endopeptidases, Serine Proteases, Peptide Hydrolases, Enzymes and Coenzymes, North and Central America, Diagnostics and Screening, Prostate Specific Antigen, Prostate-Specific Antigen.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC
Hackensack University Medical Center
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues
Medical Specialties and Practices